Capital Medical Center
Click Here to Subscribe!

E-Health Services

Daily Health News

  Latest News
  FDA Approvals
  FYI

Health Information

Newsletter Topics

Alzheimer's Disease
Anxiety
Arthritis
Blood Pressure
Breast Cancer
Cancer
Depression
Diabetes
Exercise / Fitness
Female Urological Disorders
Gastrointestinal Health
Healthy Diet
Heart Disease
Men's Health
Menopause
Neurology
Orthopedics
Pain Management
Parenting
Pediatrics
Pregnancy
Senior Caregiving
Seniors' Health
Sleep Disorders
Sports Medicine
Stroke
Weight Management
Women's Health
Women's Heart Health
Username: Password: Forgot password?
Remember me next time.
 FDA Approvals
Return to
Daily Health Main Page.
  Tweet it! Pin it!
  Siliq Approved for Plaque Psoriasis
 
  Injected drug is for use by patients who've failed other treatments

 

THURSDAY, Feb. 16, 2017 (HealthDay News) -- The injected drug Siliq (brodalumab) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe plaque psoriasis in adults.

Siliq is approved for patients who've already failed to respond to other systemic therapies, the agency noted.

The autoimmune disease -- so-called because the immune system produces antibodies that attack the body's own tissues -- causes thick, scaly patches of red skin. The drug is designed to inhibit the body's inflammatory response that plays a role in the development of plaque psoriasis, the FDA said in a news release.

The disease occurs most often in people with a family history, usually between ages 15 and 35.

Saliq was evaluated in clinical studies involving more than 4,300 people with moderate-to-severe plaque psoriasis. The most common side effects included joint pain, headache, fatigue, diarrhea, throat pain, nausea, muscle pain and injection-site reactions.

More-serious potential side effects are suicidal thoughts and behavior, especially among people with a history of suicidal behavior or depression, the FDA said. But "a causal association between treatment with Siliq and increased risk of suicidal ideation and behavior has not been established," the agency added.

The drug's label will include a boxed warning of possible suicidal thoughts and behavior, the FDA said. The agency also warned against the drug's use by people with the gastrointestinal disorder Crohn's disease or active tuberculosis.

Siliq is marketed by Valeant Pharmaceuticals, based in Bridgewater, N.J.

More information

The FDA has more about this approval.

  Print
 
 More  FDA Approvals
 
   •  Emflaza Approved for Duchenne Muscular Dystrophy
  First U.S. approval of corticosteroid to treat the disorder
 
   •  Newborn Screening Tests Approved
  The screens are used to detect four rare metabolic disorders
 
   •  Trulance Approved for Chronic Constipation
  Drug designed to stimulate upper gastrointestinal tract
 
   •  Ovarian Cancer Drug Given Fast-Track Approval
  Rubraca's use is specific to women with a mutation of the BRCA gene, FDA said
 
Health Content Provided By:
The health content is provided for informational and educational purposes. It is intended for the general population and may not reflect specific conditions or risk of an individual or segment of the population. Therefore, it is not intended to be a substitute for professional medical advice, consultation, treatment or diagnosis. Always seek the advice of your physician or other qualified health provider with questions. Never disregard professional medical advice or delay in seeking it because of information obtained through these services.
E-Home | E-Health Services | Sample News | Subscribe | Feedback | Contact Us | Privacy Policy | Terms & Conditions
 
© 2010 CAPITAL MEDICAL CENTER · 3900 CAPITAL MALL DRIVE SW · OLYMPIA, WA 98502 · 360-754-5858 · SITEMAP · PRIVACY POLICY · TERMS & CONDITIONS
 
ABOUT US SERVICES & TECHNOLOGY FOR PATIENTS & GUESTS FOR PHYSICIANS FOR EMPLOYEES COMMUNITY CAREERS